Analysis on Conbercept for exudative age-related macular degeneration

Abstract

AIM: To analyze the effect of Conbercept for exudative age-related macular degeneration(ARMD).METHODS: There were 21 eye of 21 patients with exudative ARMD from January 2016 to January 2017 included. All the patients were treated with intravitreal injection of conbercept 0.5mL(0.5mg)and followed up for 3mo. The best corrected visual acuity(BCVA)and central macular thickness(CMT)before and 1wk, 1 and 3mo after treatment were observed. RESULTS: The BCVA and CMT before and 1wk, 1 and 3mo after treatment were 0.9±1.4, 0.7±1.2, 0.5±1.1 and 0.4±0.9. BCVA after treatment were different at different time(F=49.12, PP>0.05); that at 3mo were significantly different compared with before(PF=2 487.45, PPCONCLUSION: Intravitreal injection of conbercept for exudative ARMD is remarkable.

Keywords

• exudative age-related macular degeneration
• conbercept
• conbercept